Cali Biosciences Initiates Second Phase III Study of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use and Presents Consistent and Predictable PK Results Across Multiple Surgeries

Cali Biosciences Initiates Second Phase III Study of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use and Presents Consistent and Predictable PK Results Across Multiple Surgeries

...

Cali Biosciences Initiates Phase III Studies of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use

Cali Biosciences Initiates Phase III Studies of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use

...

    •
  • 1
  • 2
    •
    menu
    menu